Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Receives $17.25 Average Target Price from Analysts

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the five ratings firms that are presently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell recommendation, three have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $17.25.

A number of research firms have weighed in on ENTA. StockNews.com raised shares of Enanta Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Wednesday, February 19th. JMP Securities reaffirmed a "market outperform" rating and set a $21.00 target price on shares of Enanta Pharmaceuticals in a report on Tuesday, February 11th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $18.00 price objective on shares of Enanta Pharmaceuticals in a research note on Tuesday, February 11th.

Enanta Pharmaceuticals Stock Down 1.7 %

Shares of NASDAQ:ENTA traded down $0.10 during midday trading on Wednesday, hitting $5.95. The stock had a trading volume of 101,428 shares, compared to its average volume of 286,420. The company has a market capitalization of $126.93 million, a P/E ratio of -1.20 and a beta of 0.81. The company's 50-day moving average price is $5.91 and its 200-day moving average price is $7.13. Enanta Pharmaceuticals has a fifty-two week low of $4.09 and a fifty-two week high of $17.24.

Enanta Pharmaceuticals (NASDAQ:ENTA - Get Free Report) last posted its quarterly earnings results on Monday, February 10th. The biotechnology company reported ($1.05) EPS for the quarter, topping analysts' consensus estimates of ($1.16) by $0.11. Enanta Pharmaceuticals had a negative return on equity of 75.53% and a negative net margin of 157.57%. Research analysts expect that Enanta Pharmaceuticals will post -4.65 EPS for the current fiscal year.

Insider Transactions at Enanta Pharmaceuticals

In other news, CEO Jay R. Luly bought 45,000 shares of Enanta Pharmaceuticals stock in a transaction dated Wednesday, February 12th. The stock was purchased at an average price of $5.69 per share, for a total transaction of $256,050.00. Following the purchase, the chief executive officer now directly owns 846,638 shares in the company, valued at $4,817,370.22. The trade was a 5.61 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 13.89% of the stock is owned by insiders.

Institutional Investors Weigh In On Enanta Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. purchased a new position in shares of Enanta Pharmaceuticals in the 4th quarter worth approximately $26,000. GAMMA Investing LLC bought a new stake in shares of Enanta Pharmaceuticals during the 1st quarter worth $40,000. Tower Research Capital LLC TRC boosted its holdings in shares of Enanta Pharmaceuticals by 46.1% in the 4th quarter. Tower Research Capital LLC TRC now owns 7,202 shares of the biotechnology company's stock worth $41,000 after buying an additional 2,274 shares during the last quarter. Intech Investment Management LLC bought a new position in Enanta Pharmaceuticals during the fourth quarter valued at about $58,000. Finally, Squarepoint Ops LLC purchased a new stake in Enanta Pharmaceuticals during the fourth quarter worth about $66,000. 94.99% of the stock is owned by institutional investors.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.